Exelixis Cashes In on Discovery
Executive Summary
Exelixis has long used business development as a strategic tool, both to acquire key capacities that have helped it build an extensive early-stage product pipeline and to creatively fund that upstream activity. Now, the biotech is beginning to convert some of that early pipeline into the cash and clinical expertise it will need to fund and run in-house product development.